Acrylamide neurotoxicity

Nutritional Neuroscience

Volumn 17, Issue 2, 2014, Pages 49-57

  Erkekoglu, Pinar ^a   Baydar, Terken ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acrylamide; Neurodegenerative diseases; Neuropathy; Neurotoxicity

Indexed keywords

ACRYLAMIDE; NEUROTOXIN; NEUROTRANSMITTER;

CELL DIVISION; DEGENERATIVE DISEASE; DOSE RESPONSE; FOOD CONTAMINATION; FOOD INTAKE; HUMAN; NEUROPATHY; NEUROTOXICITY; NEUROTRANSMISSION; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

ACRYLAMIDE; NEURODEGENERATIVE DISEASES; NEUROPATHY; NEUROTOXICITY;

ACRYLAMIDE; COOKING; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD CONTAMINATION; HOT TEMPERATURE; HUMANS; KINESIN; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; NEUROTRANSMITTER AGENTS; OCCUPATIONAL EXPOSURE; SYNAPTIC TRANSMISSION;

EID: 84893379736     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830513Y.0000000065     Document Type: Review

References (133)

1. United States Environmental Protection Agency (US EPA). 1985. Health and environmental effects profile for acrylamide. Final report 1985. Washington, DC: Office of Research and Development, U.S. EPA, p. 95. [updated 2010 March 10; cited 2012 September 30]. Available from: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=47199
2. United States Environmental Protection Agency (US EPA). 1988. Methodology for evaluating potential carcinogenicity in support of reportable quantity adjustments pursuant to CERCLA Section 102. Washington, DC: Carcinogen Assessment Group, Office of Health and Environmental Assessment, U S. EPA, pp. 21-22.
3. Spencer PS, Schaumburg HH. A review of acrylamide neuro-toxicity. Part I. Properties, uses and human exposure. Can J Neurol Sci 1974;1:143-150.
4. Spencer PS, Schaumburg HH. A review of acrylamide neuro-toxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can J Neurol Sci 1974;1:152-169.
5. Tilson HA. 1981. The neurotoxicity of acrylamide: an overview. Neurobehav Toxicol Teratol 3:445-461.
6. Friedman M. Chemistry, biochemistry, and safety of acryl-amide. A review. Agric Food Chem 2003;51:4504-526.
7. Wenzl T, De La Calle MB, Anklam E. Analytical methods for the determination of acrylamide in food products: a review. Food Addit Contam 2003;20:885-902.
8. Lopachin RM, Gavin T. Acrylamide-induced nerve terminal damage: relevance to neurotoxic and neurodegenerative mechanisms. J Agric Food Chem 2008;56:5994-6003.
9. Tareke E, Rydberg P, Karlsson P, Eriksson S, Törnqvist M. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric Food Chem 2002;50:4998-5006.
10. Blancher C, Cormick RM. Sodium dodecyl sulphate-polyacryl-amide denaturing gel electrophoresis and Western blotting techniques. Methods Mol Biol 2012;878:89-110.
11. Garzotti M, Rovatti L, Hamdan M. On-line liquid chromato-graphy/electrospray tandem mass spectrometry to investigate acrylamide adducts with cysteine residues: implications for polyacrylamide gel electrophoresis separations of proteins. Rapid Commun Mass Spectrom 1998;12:484-488.
12. Viator C, Muth MK. Acrylamide: the next food safety issue. Choices [cited serial online] 2004; 1st Quarter: 13-7 [cited September 30] [accessed on January 25, 2010]. Available from: http://www.choicesmagazine.org/2004-1/2004-1-03.pdf.
13. Choe E, Min DB. Chemistry and reactions of reactive oxygen species in foods. Crit Rev Food Sci Nutr 2006;46:1-22.
14. Becalski A, Lau BPY, Lewis D, Seaman S. 2002. Acrylamide in foods: occurrence and sources. Abstracts; 116th Annual AOAC International Meeting, Los Angeles, CA, September 26, 2002. Gaithersburg, MD: AOAC.
15. Zhang Y, Ren Y, Jiao J, Li D, Zhang Y. Ultra high-performance liquid chromatography-tandem mass spectrometry for the simultaneous analysis of asparagine, sugars, and acrylamide in Maillard reactions. Anal Chem 2011;83:3297-3304.
16. Woodrow JE, Seiber JN, Miller GC. Acrylamide release resulting from sunlight irradiation of aqueous polyacrylamide/iron mixtures. J Agric Food Chem 2008;56:2773-2779.
17. Schettgen T, Weiss T, Drexler H, Angerer J. A first approach to estimate the internal exposure to acrylamide in smoking and non-smoking adults from Germany. Int J Hyg Environ Health 2003;206:9-14.
18. Lantz I, Ternité R, Wilkens J, Hoenicke K, Guenther H, van der Stegen GH. Studies on acrylamide levels in roasting, storage and brewing of coffee. Mol Nutr Food Res 2006;50: 1039-1046.
19. Calleman CJ. The metabolism and pharmacokinetics of acryl-amide: implications for mechanisms of toxicity and human risk estimation. Drug Metab Rev 1996;28:527-590.
20. Bergmark E, Calleman CJ, He F, Costa LG. Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol Appl Pharmacol 1993;120:45-54.
21. Sumner SC, Fennell TR, Moore TA, Chanas B, Gonzalez F, Ghanayem BI. Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 1999;12:1110-1116.
22. Dybing E, Sanner T. Risk assessment of acrylamide in foods. Toxicol Sci 2003;75:7-15.
23. Carere A. Genotoxicity and carcinogenicity of acrylamide: a critical review. Ann Ist Super Sanita 2006;42:144-155.
24. Baum M, Fauth E, Fritzen S, Herrmann A, Mertes P, Rudolphi M, et al. Acrylamide and glycidamide: approach towards risk assessment based on biomarker guided dosimeter of geno-toxic/mutagenic effects in human blood. Adv Exp Med Biol 2005;561:77-88.
25. Segerbäck D, Calleman CJ, Schroeder JL, Costa LG, Faustman EM. Formation of N-7-(2-carbamoyl-2-hydroxyethyl)guanine in DNA of the mouse and the rat following intraperitoneal administration of [14C]acrylamide. Carcinogenesis 1995;16: 1161-1165.
26. Costa LG, Deng H, Gregotti C, Manzo L, Faustman EM, Bergmark E, et al. Comparative studies on the neuro- and reproductive toxicity of acrylamide and its epoxide metabolite glycidamide in the rat. Neurotoxicology 1992;13:219-224.
27. Paulsson B, Kotova N, Grawé J, Henderson A, Granath F, Golding B, et al. Induction of micronuclei in mouse and rat by glycidamide, genotoxic metabolite of acrylamide. Mutat Res 2003;535:15-24.
28. Smith EA, Oehme FW. Acrylamide and polyacrylamide: a review of production, use, environmental fate and neurotoxi-city. Rev Environ Health 1991;9(4):215-228.
29. Fullerton PM, Barnes JM. Peripheral neuropathy in rats produced by acrylamide. Br J Ind Med 1966;23:210-221.
30. Gillette JR. Commentary. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. I. Correlation of changes in covalent binding of reactivity metabolites with changes in the incidence and severity of toxicity. Biochem Pharmacol 1974;23:2785-2794.
31. Gillette JR. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. II. Alterations in the kinetics of covalent binding. Biochem Pharmacol 1974; 23:2927-2938.
32. Rozman KK, Klaassen CD. Absorption, distribution and excretion of toxicants. In Klaassen CD (ed.) Toxicology: the basic science of poisons. New York: McGraw-Hill, 2001. p. 07-132.
33. Hoffmann KJ, Streeter AJ, Axworthy DB, Baillie TA. Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins. Mol Pharmacol 1985;27:566-573.
34. Beauchamp Jr, RO, Andjelkovich DA, Kligerman AD, Morgan KT, Heck HD. A critical review of the literature on acrolein toxicity. Crit Rev Toxicol 1985;14:309-380.
35. Feron VJ, Kruysse A, Til HP, Immel HR. Repeated exposure to acrolein vapour: subacute studies in hamsters, rats and rabbits. Toxicology 1978;9:47-57.
36. Green MA, Egle Jr, JL. The effects of acetaldehyde and acro-lein on blood pressure in guanethidine-pretreated hypertensive rats. Toxicol Appl Pharmacol 1983;69:29-36.
37. Barber DS, Hunt JR, Ehrich MF, Lehning EJ, LoPachin RM. Metabolism, toxicokinetics and hemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing. Neurotoxicology 2001;22:341-353.
38. LoPachin RM, Gavin T, Geohagen BC, Das S. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft soft interactions described by quantum mechanical parameters. Toxicol Sci 2007;98:561-570.
39. Niemelä O. Distribution of ethanol-induced protein adducts in vivo: relationship to tissue injury. Free Radic Biol Med 2001;31: 1533-1538.
40. Trenga CA, Kunkel DD, Eaton DL, Costa LG. Effect of styrene oxide on rat brain glutathione. Neurotoxicology 1991; 12:165-178.
41. Pruser KN, Flynn NE. Acrylamide in health and disease. Front Biosci (Schol Ed) 2011;3:41-51.
42. Besaratinia A, Pfeifer GP. A review of mechanisms of acryl-amide carcinogenicity. Carcinogenesis 2007;28:519-528.
43. Dourson M, Hertzberg R, Allen B, Haber L, Parker A, Kroner O, et al. Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide. Regul Toxicol Pharmacol 2008;52:264-289.
44. National Toxicology Program. U.S. Department of Health and Human Sciences. Center for the Evaluation of Risks to Human Reproduction (NTP CERHR). NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of acryl-amide. Birth Defects Res B Dev Reprod Toxicol 2005;74: 17-113.
45. National Toxicology Program (NTP). Center for the evaluation of risks to human reproduction. [document on the Internet]. 2005. [cited 2012 February 30]. Available from: http://ntp.niehs.nih.gov/ntp/ohat/acrylamide/Acrylamide_Monograph.pdf
46. United States Environmental Protection Agency. Office of pollution prevention and Toxics. Chemical Summary for Acrylamide [document on the Internet]. 1994 [cited 2012 February 30]. Available from: http://www.epa.gov/chemfact/s_acryla.txt.
47. Johnson KA, Gorzinski SJ, Bodner KM, Campbell RA, Wolf CH, Friedman MA, et al. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol 1986;85:154-168.
48. European Commission, European Chemicals Bureau, Institute for Health and Consumer Protection, European Union Risk Assessment Report Acrylamide. Office for Official Publication of the European Communities [document on the Internet]. Luxembourg. Scientific Committee on Cosmetic Products and Non-Food Products 1999. [cited 2012 February 20]. Available from: http://www.math.uni_bremen.de/riskom/pqra_ws_2004/beispiele/acrylamid/EU_RAR_Acrylamide.pdf.
49. Opinion of the Scientific Committee on cosmetic products and nonfood products intended for consumers concerning acryl-amide residues in cosmetics adopted by the Plenary session of SCCNFP [document on the Internet]. 1999. [cited 2010 September 30]. Available from: http://ec.europa.eu/health/scientific_committees/consumersafety/opinions/sccnfp_opi nions_97_04/sccp_out95_en.htm.
50. Marsh GM, Lucas LJ, Youk AO, Schall LC. Mortality patterns among workers exposed to acrylamide: 1994 follow up. Occup Environ Med 1999;56:181-190.
51. Exon JH. A review of the toxicology of acrylamide. J Toxicol Environ Health B Crit Rev 2006;9:397-412.
52. FAO/WHO Consultation Report on the health implications of acrylamide in food. Summary report. Geneva. 25-27 June 2002.
53. Konings EJ, Baars AJ, van Klaveren JD, Spanjer MC, Rensen PM, Hiemstra M, et al. Acrylamide exposure from foods of the Dutch population and an assessment of the consequent risks. Food Chem Toxicol 2003;41:1569-1579.
54. Lineback DR, Coughlin JR, Stadler RH. Acrylamide in foods: a review of the science and future considerations. Annu Rev Food Sci Technol 2012;3:15-35.
55. Pelucchi C, La Vecchia C, Bosetti C, Boyle P, Boffetta P. Exposure to acrylamide and human cancer-a review and meta-analysis of epidemiologic studies. Ann Oncol 2011;22: 1487-1499.
56. Dybing E, Farmer PB, Andersen M, Fennell TR, Lalljie SP, Müller DJ, et al. Human exposure and internal dose assessments of acrylamide in food. Food Chem Toxicol 2005;43: 365-410.
57. United States Food and Drug Administration Public Meeting Assessing Acrylamide in the U.S. Food Supply. David R. Lineback, Director [document on the Internet]. 2002. [cited 2012 September 30]. Available from: http://www.fda.gov/ohrms/dockets/dailys/02/Oct02/100402/02n-0393-ts00007-lineback.pdf
58. World Health Organization Meeting. Food Safety Consultations. Report of a Joint FAO/WHO Consultation WHO Headquarters, Geneva, Switzerland [document on the Internet]. 2002 [cited 2012 September 30]. Available from: http://www.who.int/foodsafety/publications/chem/en/acrylamide_full.pdf
59. Erkekoglu P, Baydar T. Toxicity of acrylamide and evaluation of its exposure in baby foods. Nutr Res Rev 2010;23:323-333.
60. LoPachin RM. The changing view of acrylamide neurotoxicity. Neurotoxicology 2004;25:617-630.
61. Müller M, Wacker K, Getts D, Ringelstein EB, Kiefer R. Further evidence for a crucial role of resident endoneurial macrophages in peripheral nerve disorders: lessons from acryl-amide-induced neuropathy. Glia 2008;56:1005-1016.
62. LoPachin Jr, RM, Lehning EJ. Acrylamide-induced distal axon degeneration: a proposed mechanism of action. Neurotoxicology 1994;15:247-259.
63. LoPachin RM, Ross JF, Reid ML, Das S, Mansukhani S, Lehning EJ. Neurological evaluation of toxic axonopathies in rats: acrylamide and 2,5-hexanedione. Neurotoxicology 2002; 23:95-110.
64. LoPachin RM, Balaban CD, Ross JF. Acrylamide axonopathy revisited. Toxicol Appl Pharmacol 2003;188:135-153.
65. Deng H, He F, Zhang S, Calleman CJ, Costa LG. Quantitative measurements of vibration threshold in healthy adults and acrylamide workers. Int Arch Occup Environ Health 1993;65: 53-56.
66. He FS, Zhang SL, Wang HL, Li G, Zhang ZM, Li FL, et al. Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ Health 1989;15:125-129.
67. Abelli L, Ferri GL, Astolfi M, Conte B, Geppetti P, Parlani M, et al. Acrylamide-induced visceral neuropathy: evidence for the involvement of capsaicin-sensitive nerves of the rat urinary bladder. Neuroscience 1991;41:311-321.
68. Satchell PM. Abnormalities of sympathetic vasomotor tone in distal axonal neuropathy. J Neurol Sci 1989;90:251-261.
69. Post EJ, McLeod JG. Acrylamide autonomic neuropathy in the cat. Part 2. Effects on mesenteric vascular control. J Neurol Sci 1977;33:375-85.
70. Satchell PM. Baroreceptor dysfunction in acrylamide axonal neuropathy. Brain 1990;113:167-176.
71. LoPachin RM. The role of fast axonal transport in acrylamide pathophysiology: mechanism or epiphenomenon? Neurotoxicology 2002;23:253-257.
72. Hagmar L, Törnqvist M, Nordander C, Rosén I, Bruze M, Kautiainen A, et al. Health effects of occupational -exposure to acrylamide using hemoglobin adducts as biomarkers of internal dose. Scand J Work Environ Health 2001;27:219-226.
73. Miller MS, Spencer PS. The mechanisms of acrylamide axono-pathy. Annu Rev Pharmacol Toxicol 1985;25:643-666.
74. McCollister DD, Oyen F, Rowe VK. Toxicology of acrylamide. Ther Ggw 1964;103:172-181.
75. Allam A, El-Ghareeb AA, Abdul-Hamid M, Baikry A, Sabri MI. Prenatal and perinatal acrylamide disrupts the development of cerebellum in rat: Biochemical and morphological studies. Toxicol Ind Health 2011;27:291-306.
76. Adler ID, Zouh R, Schmid E. Perturbation of cell division by acrylamide in vitro and in vivo. Mutat Res 1993;301:249-254.
77. Thomann P, Koella WP, Krinke G, Peterman H, Zak G, Hess R. The assessment of peripheral neurotoxicity in dogs: Comparative studies with acrylamide and clioquinol. Agent Actions 1974;4:47-53.
78. Lapin EP, Maker HS, Weissbarth S, Weiss C, Lehrer GM. The influence of systemic factors on acrylamide-induced changes in brain, nerve, and othertissues. J Neurosci Res 1984;11:395-404.
79. Hattis D, Shapiro K. Analysis of dose/time/response relationships for chronic toxic effects: the case of acrylamide. Neurotoxicology 1990;11:219-236.
80. Hopkins A. The effect of acrylamide on the peripheral nervous system of the baboon. J Neurol Neurosurg Psychiatry 1970;33: 805-816.
81. Klaunig JE, Kamendulis LM. Mechanisms of acrylamide induced rodent carcinogenesis. Adv Exp Med Biol 2005;561: 49-62.
82. Klaunig JE. Acrylamide carcinogenicity. J Agric Food Chem 2008;56:5984-5988.
83. Lehning EJ, LoPachin RM, Mathew J, Eichberg J. Changes in Na-K ATPase and protein kinase C activities in peripheral nerve of acrylamide-treated rats. J Toxicol Environ Health 1994;42:331-342.
84. Yu S, Zhao X, Zhang T, Yu L, Li S, Cui N, et al. Acrylamide-induced changes in the neurofilament protein of rat cerebrum fractions. Neurochem Res 2005;30:1079-1085.
85. LoPachin RM. Redefining toxic distal axonopathies. Toxicol Lett 2000;112-113:23-33.
86. Kaji R, Liu Y, Duckett S, Sumner AJ. Slow recovery of central axons in acrylamide neuropathy. Muscle Nerve 1989;12: 816-826.
87. Suzuki K, Pfaff LD. Acrylamide neuropathy in rats. An electron microscopic study of degeneration and regeneration. Acta Neuropathol 1973;24:197-213.
88. Gold BG, Schramburg HH. 2000. Acrylamide. In Spencer PS, Schramburg HH (eds.) Experimental and clinic neurotoxicol-ogy 2nd ed. New York: Oxford University Press. p. 124-132.
89. Cavanagh JB. The pathokinetics of acrylamide intoxication: a reassessment of the problem. Neuropathol Appl Neurobiol 1982;8:315-336.
90. LoPachin RM, Jones RC, Patterson TA, Slikker W, Barber DS. Application of proteomics to the study of molecular mechanisms in neurotoxicology. Neurotoxicology 2003;24:761-775.
91. Sabri MI, Spencer PS. How does acrylamide perturb axon transport and induce nerve fiber degeneration? Commentary on forum position paper. Neurotoxicology 2002;23:259-263.
92. Sickles DW, Brady ST, Testino A, Friedman MA, Wrenn RW. Direct effect of the neurotoxicant acrylamide on kinesin-based microtubule motility. J Neurosci Res 1996;46:7-17.
93. Höke A. Neuroprotection in the peripheral nervous system. Rationale for more effective therapies. Arch Neurol 2006;63: 1681-1685.
94. Murray L. Acrylamide [document on the Internet]. 1996. [updated 1999 June; cited 2012 September 30]. Available from: http://www.inchem.org/documents/pims/chemical/pim652.htm.
95. Spencer PS, Schaumburg HH. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopa-thies. J Neuropathol Exp Neurol 1977;36:300-320.
96. LoPachin RM, Ross JF, Lehning EJ. Nerve terminals as the primary site of acrylamide action: a hypothesis. Neurotoxicology 2002;23:43-59.
97. +-ATPase identified as a ouabain binding site in rat sciatic nerve. Neurosci Lett 1986;64:177-183.
98. Mata M, Datta S, Jin CF, Fink DJ. Differential axonal transport of individual Na,K-ATPase catalytic (alpha) subunit iso-forms in rat sciatic nerve. Brain Res 1993;618:295-298.
99. Mannaa F, Abdel-Wahhab MA, Ahmed HH, Park MH. Protective role of Panax ginseng extract standardized with gin-senoside Rg3 against acrylamide-induced neurotoxicity in rats. J Appl Toxicol 2006;26:198-206.
100. Lehning EJ, Gaughan CL, LoPachin Jr, RM. Acrylamide intoxication modifies in vitro responses of peripheral nerve axons to anoxia. J Peripher Nerv Syst 1997;2:165-174.
101. Lehning EJ, Persaud A, Dyer KR, Jortner BS, LoPachin RM. Biochemical and morphologic characterization of acrylamide peripheral neuropathy. Toxicol Appl Pharmacol 1998;151: 211-221.
102. Amaratunga A, Fine RE. Generation of amyloidogenic C-terminal fragments during rapid axonal transport in vivo of beta-amyloid precursor protein in the optic nerve. J Biol Chem 1995;270:17268-17272.
103. Lasek RJ, Garner JA, Brady ST. Axonal transport of the cyto-plasmic matrix. J Cell Biol 1984;99:212s-21s.
104. Erecińska M, Nelson D, Yudkoff M, Silver IA. Energetics of the nerve terminal in relation to central nervous system function. Biochem Soc Trans 1994;22:959-965.
105. Medrano CJ, LoPachin RM. Effects of acrylamide and 2,5-hex-anedione on brain mitochondrial respiration. Neurotoxicology 1989;10:249-255.
106. Sickles DW, Fowler SR, Testino AR. Effects of neurofilamen-tous axonopathy-producing neurotoxicants on in vitro production of ATP by brain mitochondria. Brain Res 1990;528: 25-31.
107. Tyl RW, Friedman MA. Effects of acrylamide on rodent reproductive performance. Reprod Toxicol 2003;17:1-13.
108. Cao J, Liu Y, Jia L, Jiang LP, Geng CY, Yao XF, et al. Curcumin attenuates acrylamide-induced cytotoxicity and gen-otoxicity in HepG2 cells by ROS scavenging. J Agric Food Chem 2008;56:12059-1263.
109. Zhang X, Jiang L, Geng C, Yoshimura H, Zhong L. Inhibition of acrylamide genotoxicity in human liver-derived HepG2 cells by the antioxidant hydroxytyrosol. Chem Biol Interact 2008; 176:173-178.
110. Odland L, Romert L, Clemedson C, Walum E. Glutathione content, glutathione transferase activity and lipid peroxidation in acrylamide-treated neuroblastoma N1E 115 cells. Toxicol In Vitro 1994;8:263-267.
111. Mei N, McDaniel LP, Dobrovolsky VN, Guo X, Shaddock JG, Mittelstaedt RA, et al. The genotoxicity of acrylamide and glycidamide in big blue rats. Toxicol Sci 2010;15:412-421.
112. Calleman CJ, Stern LG, Bergmark E, Costa LG. Linear versus nonlinear models for hemoglobin adduct formation by acrylamide and its metabolite glycidamide: implications for risk estimation. Cancer Epidemiol Biomarkers Prev 1992;1: 361-368.
113. Carlson GP, Weaver PM. Distribution and binding of [14C]acrylamide to macromolecules in SENCAR and BALB/ c mice following oral and topical administration. Toxicol Appl Pharmacol 1985;79:307-313.
114. Smith EA, Oehme FW. Acrylamide and polyacrylamide: a review of production, use, environmental fate and neurotoxi-city. Rev Environ Health 1991;9:215-228.
115. Xiwen H, Jing L, Tao C, Ke Y. Studies on biochemical mechanism of neurotoxicity induced by acrylamide in rats. Biomed Environ Sci 1992;5:276-281.
116. Reagan KE, Wilmarth KR, Friedman M, Abou-Donia MB. Acrylamide increases in vitro calcium and calmodulin-dependent kinase-mediated phosphorylation of rat brain and spinal cord neurofilament proteins. Neurochem Int 1994;25: 133-143.
117. Fu PP, Von Tungeln LS, Hammons GJ, McMahon G, Wogan G, Flammang TJ, et al. Metabolic activation capacity of neonatal mice in relation to the neonatal mouse tumorigenicity bioassay. Drug Metab Rev 2000;32:241-266.
118. Lopachin RM, Decaprio AP. Protein adduct formation as a molecular mechanism in neurotoxicity. Toxicol Sci 2005;86: 214-225.
119. Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurode-generation: new insights into Alzheimer's disease. Curr Opin Lipidol 2002;13:289-94.
120. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 2002;33:620-626.
121. Sultana R, Perluigi M, Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med 2012 Oct 5.pii: S0891-5849(12)01161-6. doi: 10.1016/j.freeradbiomed. 2012.09.027.
122. Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002;184:187-197.
123. LoPachin RM, Barber DS, Gavin T. Molecular mechanisms of the conjugated alpha,beta-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases. Toxicol Sci 2008;104235-104249.
124. Luo J, Shi R. Acrolein induces oxidative stress in brain mitochondria. Neurochem Int 2005;46:243-252.
125. Lopachin RM, Gavin T. Molecular mechanism of acrylamide neurotoxicity: lessons learned from organic chemistry. Environ Health Perspect 2012 Dec;120(12):1650-1657.
126. McCracken E, Valeriani V, Simpson C, Jover T, McCulloch J, Dewar D. The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J Cereb Blood Flow Metab 2000;20:1529-1536.
127. Tang SC, Arumugam TV, Cutler RG, Jo DG, Magnus T, Chan SL, et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem 2007;101: 729-736.
128. Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 2003;24:1023-1027.
129. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001;22:187-94.
130. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 2003;24:1029-1046.
131. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
132. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997;17: 5089-5100.
133. Lopachin RM, Gavin T, Barber DS. Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases. Neurotoxicology 2008;29:871-882.